Novartis

Explore the latest insights on Novartis and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Novartis’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Novartis, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Novartis please access flcube.com

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

China's Ministry of Commerce (MOFCOM) and the Ministry of Science and Technology (MOST) jointly launched a public consultation on proposed revisions to the Catalogue of Technologies Prohibited or Restricted from…

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

CompanyDeals

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

CompanyDeals

MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer

CompanyDrug

Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group

CompanyLegal / IP

Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case

Company

Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration

CompanyDrug

FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up

CompanyDeals

Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion

Show More